Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer
Status:
Terminated
Trial end date:
2018-09-01
Target enrollment:
Participant gender:
Summary
NC-6004 is a polymeric micelle containing cisplatin as an active moiety. The nanoparticle
provides sustained release of the active moiety and utilizes the enhanced permeability and
retention (EPR) effect to target release of platinum to tumors. This Phase I study aims to
establish a recommended dose (RD) for the triplet combination of NC-6004 plus 5-FU and
cetuximab as first-line treatment in patient with recurrent and/or metastatic squamous cell
carcinoma of the head and neck for further clinical study development.